Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications
Objective: To describe the different combinations of dopaminergic drugs at the early stage of Parkinson’s disease (PD) in a real-life cohort, and to determine their…VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)
Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…Prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population
Objective: To know the prevalence and clinical characteristics of young onset Parkinson’s Disease among Nepalese Population Background: Parkinson’s disease (PD) is a neurodegenerative disease which…Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.
Objective: Gaucher disease is an inherited disease caused by a mutation in the glucocerebrosidase gene, causing visceral, hematologic, and skeletal involvement. [1] [2] We report…Response of extraocular movements in parkinson’s disease to levodopa: an electrooculographic perspective
Objective: To determine the response of latencies and amplitudes of saccadic movements to Levodopa in idiopathic Parkinson’s Disease. Background: Neurodegeneration in Parkinson’s Disease (PD) increases…Feasibility, Reliability and Value of Remote Levodopa Challenge Test in Parkinson’s Disease
Objective: To demonstrate the feasibility, reliability, and value of the remote L-dopa challenge test (LCT) in candidate screening for deep brain stimulation (DBS) in patients…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 57
- Next Page »